Deka Biosciences, a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis and sepsis, is breaking ground on a 14,000 square foot office and lab which will house a state-of-the-art research and development, process development and manufacturing facility to further develop their cytokine therapies. According to the company, this will be the first facility to house a dual targeted cy...